

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Appraisal

Ozanimod for treating moderately to severely active ulcerative colitis ID3841

Provisional Stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Celgene (a Bristol-Myers Squibb company) (ozanimod) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Bladder and Bowel Community • Colostomy UK • CIRCA - Children with Crohn's and Colitis Association • Crohn's and Colitis UK • GUTS UK • South Asian Health Foundation • Specialised Healthcare Alliance Ulcerative Colitis UK <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Coloproctology for Great Britain and Ireland • British Geriatrics Society • British Society of Gastroenterology • Primary Care Society for Gastroenterology • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Society of Medicine • Royal Pharmaceutical Society • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS South Devon and Torbay CCG • NHS Wiltshire CCG • Welsh Government 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Scottish Society of Gastroenterology • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • AbbVie (adalimumab) • Amgen Europe (adalimumab) • Biogen Idec (adalimumab, infliximab) • Boehringer Ingelheim International (adalimumab) • Celltrion Healthcare (infliximab) • Fresenius Kabi (adalimumab) • Janssen-Cilag (ustekinumab) • Merck Sharp & Dohme (infliximab, golimumab) • Mylan (adalimumab) • Napp Pharmaceuticals (infliximab) • Pfizer (infliximab, tofacitinib) • Samsung Bioepis UK (adalimumab, infliximab) • Sandoz (adalimumab, infliximab) • Takeda UK (vedolizumab)

Consultees	Commentators (no right to submit or appeal)
	<p data-bbox="833 262 1174 293"><u>Relevant research groups</u></p> <ul data-bbox="833 297 1394 465" style="list-style-type: none"> <li data-bbox="833 297 1394 360">• Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group <li data-bbox="833 365 1134 396">• Genomics England <li data-bbox="833 400 1198 432">• MRC Clinical Trials Unit <li data-bbox="833 436 1374 468">• National Institute for Health Research <p data-bbox="833 504 1262 535"><u>Associated Public Health groups</u></p> <ul data-bbox="833 539 1174 602" style="list-style-type: none"> <li data-bbox="833 539 1174 571">• Public Health England <li data-bbox="833 575 1147 607">• Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.